Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

[18F]Flubatine: a Novel Biomarker of Cholinergic a4ß2 Nicotinic Receptors and Cognition in Parkinson's Disease

NCT02076295 is registered in ClinicalTrials.gov with University of Michigan as lead sponsor.

NCT NCT02076295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
[18F]Flubatine: a Novel Biomarker of Cholinergic a4ß2 Nicotinic Receptors and Cognition in Parkinson's Disease
Lead sponsor
University of Michigan
Phase
Observational
Overall status
Completed
Start date
February 28, 2014
Completion date
December 30, 2016
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease